Archief

Potentia RL CBT307-1 (Imaging)

29 november 2022

A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA-Tumour Lesions Eudractnummer: 2021-006256-13 CB307 is een trispecifieke Humabody® gericht op CD137; PSMA; en humaan serumalbumine…

CYCLONE-3

24 november 2022

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer EU trial number: 2022-500461-28-06 Samenvatting…

EORTC1976 – TOLERANCE

9 november 2022

A 3 arm randomized study on health-related quality of life of elderly patients with advanced soft tissue sarcoma undergoing doxorubicin every three weeks or doxorubicin weekly or cyclophosphamide…

INCB81776-101

13 oktober 2022

A Phase 1a/1b Study exploring the safety and tolerability of INCB081776 +/- retifanlimab in participants with advanced malignancies Protocol: INCB 81776-101 EudraCT Number: 2020-004867-26 Een Fase 1a/1b, open label…

INCB81776-101

10 oktober 2022

A Phase 1a/1b Study exploring the safety and tolerability of INCB081776 +/- retifanlimab in participants with advanced malignancies Protocol: INCB 81776-101 EudraCT Number: 2020-004867-26 Een Fase 1a/1b, open label…

MK3475-C93

13 september 2022

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in…

CEMangio

4 juli 2022

Behandeling met cemiplimab van patiënten met lokaal vergevorderd of gemetastaseerd secundair angiosarcoom. Eudractnummer: 2020-005465-13 Samenvatting In deze fase II studie kunnen patiënten met een lokaal vergevorderd of gemetastaseerd…

Ave-short-trial

11 mei 2022

Een nationaal, multicenter, niet-geblindeerde doelmatigheids studie waarbij zes maanden avelumab onderhoudsbehandeling wordt gegeven aan patienten met een lokaal gevorderd of gemetastaseerde urotheelcarcinoom zonder ziekteprogressie na minimaal 4 kuren…

R2810-ONC-ISA-1981

17 februari 2022

A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients with Recurrent/Metastatic HPV16 Cervical Cancer who have Experienced Disease Progression after ≥First Line…

OncoLifeS Immunotherapie

13 januari 2022

HER2CLIMB-02

6 september 2021

Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer Protocolnummer: SGNTUC-016 Eudractnummer:…

Destiny-PanTumor02

15 juni 2021

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) Protocolnummer D967VC00001…

M15-913

12 april 2021

An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies. M15-913 Protocolnummer: M15-913 Eudract nummer: 2016-003887-37 METc…

GALLOP-11

Validation of mutation analysis in circulating tumour DNA with a ddPCR assay as diagnostic and follow-up tool for patients with a KIT exon 11 mutated GIST: GALLOP-11. Protocolnummer:…

EORTC 1403 / rEECur

International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma Eudractnummer: 2014-000259-99 Dit is een prospectief, multicenter, gerandomiseerd en open-label fase II/fase…

Sunniforecast

A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal…